On behalf of the Israel Cooperative Lymphoma Group. A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler, I. Ben-Bassat and A.

Size: px
Start display at page:

Download "On behalf of the Israel Cooperative Lymphoma Group. A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler, I. Ben-Bassat and A."

Transcription

1 Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan for patients with advanced highrisk Hodgkin s lymphoma A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler, I. Ben-Bassat and A. Polliack On behalf of the Israel Cooperative Lymphoma Group

2 GHLSG-HD9: escbeacopp is superior to COPP/ABVD COPP/ ABVD Escalated BEACOPP p % CR NS Early progression (at 5 yr) 10 2 <0.01 FFTF (at 5 yr) <0.01 OS (at 5 yr) Adapted from Diehl V. et al.; NEJM, 2003.

3 The superiority of escbeacopp is most evident in patients with a poor IPS Diehl V. et al.; NEJM, X escbeacopp have high incidence of acute and long term toxicities: Grade 3/4 leukopenia (98%), thrombocytopenia (70%), anemia (66%) Grade 3/4 infections - 22% AML (10 yr) - 3% Infertility -male: ~80%, female: ~100%

4 Two cycles of escbeacopp followed by four cycles of ABVD in patients with advanced HL and high IPS score: a phase II study Aims of the study: attempt to reduce toxicity while preserving improved initial tumor control employ the international prognostic score to tailor treatment at diagnosis collect data on early versus late responders according to the findings on PET scans, carried out early after 2 cycles of escbeacopp

5 Combined escbeacopp-abvd - scheme Unfavorable stage IIB or stages III, IV decision according to IPS IPS 3 IPS = X escbeacopp 6 X ABVD Re-evaluation by PET/CT *CR- PET negative with residual mass of any size PR- residual FDG uptake at previously involved sites & reduction of masses > 50% *good response (CR or PR) 4 X ABVD PD or NR Salvage + ASCT

6 PET/CT-FDG analyses PET/CT scans were scored as positive or negative for disease activity based only on visual assessment. Semiquantitative analyses were not used. Definition of disease status: CR- PET negativity with or without a residual mass of any size PR- presence of one or more PET-positive residual lesions at previously involved sites and a size reduction of the majority of large masses by >50% PD- >50% increase in the largest diameter of any residual PETpositive lesion identified in the early interim PET/CT or when any new PET-positive findings developed

7 Characteristics of patients Total Median age yrs (range) Male sex n (%) Histology: n (%) Nodular sclerosis Mixed cellularity Unclassified Stages: n (%) IIB III IV Bulky mediastinum n (%) Extranodal involvement: n (%) Bone marrow Bone Lung Liver International prognostic score n (%) (18-59) 32 (71) 34 (75) 7 (15) 4 (10) 3 (7) 9 (20) 33 (73) 15 (33) 33 (73) (69) 13 (29) 1 (2)

8 Response after completing all therapy according to early-interim PET results Early interim PET results Negative n=31 (71%) Positive n=13 (29%) Total* n=44 CR (89%) PR (7%) PD (4%) *One patient - non-fdg-avid disease at the time of diagnosis. CR at the end of therapy.

9 Overall survival 1.00 a l u rviv s l a e r o v yr - 95% months

10 Progression-free survival 1.00 a l iv u rv e s e n -fr io e ss g r p r o yr - 78% months

11 Outcome of patients according to results of early FDG-PET *Early PET negative (pts.) 31 *Early PET positive (pts.) 13 CR PD 30 1 End of therapy CR PR/PD 9 4 CR Relapse 27 3 Follow up CR Relapse 7 2 *non FDG-avid 1 patient.

12 The role of early-interim PET as predictive of progression-free survival PET- PET+ 4-yr: 87% vs. 53% Early PET predicted the outcome in 75% of patients (33/44) Positive predictive value 45% Negative predictive value 87%

13 Combined escbeacopp - ABVD: adverse effects 2 X escbeacopp ABVD All therapy Leukopenia grade 3-4 (%) Thrombocytopenia grade 3-4 (%) Infections grade 4 (%) Hospitalization (%) Avascular necrosis (n) Cognitive impairment (n) AML/MDS (n) Toxic deaths (n)

14 Two cycles of escbeacopp followed by four cycles of ABVD in patients with advanced HL and high IPS score: Conclusions Therapy is well tolerated and associated with relatively low rates of acute toxicities. Higher survival rates than expected for high risk advanced stage HL patients, receiving other ABVD containing regimens Early-interim PET had a relatively high NPV but a much lower PPV. The results of early-interim PET had a significant long-term prognostic role in the treatment of those patients receiving this regimen.

15 Thanks to all the participating centers: Chaim Sheba Medical center Soroka Medical Center Rambam Medical Center Assaf-Harofeh Hospital Laniado Hospital Tel-Aviv Medical Center Barzilai Medical Center Hadassah Medical Center Golda-Hasharon Hospital Meir Hospital Rabin Medical Center Shaare-Zedek Hospital

ABVD or BEACOPP for advanced Hodgkin lymphoma. Not to BEACOPP. Massimo Federico University of Modena and Reggio Emilia Italy

ABVD or BEACOPP for advanced Hodgkin lymphoma. Not to BEACOPP. Massimo Federico University of Modena and Reggio Emilia Italy ABVD or BEACOPP for advanced Hodgkin lymphoma Not to BEACOPP Massimo Federico University of Modena and Reggio Emilia Italy What is the best Induction Therapy for Advanced Hodgkin Lymphoma? How to treat

More information

Interim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal

Interim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Interim PET Hodgkin s Disease Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Why is this a Question? Early Advanced ipet ABVD + RT ABVD Pos Neg ABVD Beacopp Escalation Salvage Deescalation Talk outline

More information

PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD

PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies

More information

Hodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP. Volker Diehl for the German Hodgkin Study Group

Hodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP. Volker Diehl for the German Hodgkin Study Group Hodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP Volker Diehl for the German Hodgkin Study Group Moscow 25.October 2007 HD8 trial design CS IA, IB, IIA,B with risk factors Random

More information

PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma

PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer

More information

Lymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?

Lymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient? Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte

More information

PET-imaging: when can it be used to direct lymphoma treatment?

PET-imaging: when can it be used to direct lymphoma treatment? PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict

More information

LYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France

LYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing

More information

HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)

HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff

More information

Role of PET in staging and treatment of lymphomas

Role of PET in staging and treatment of lymphomas Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Madrid, 25 November 2016 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging

More information

Hodgkin. The PET World. Sally Barrington

Hodgkin. The PET World. Sally Barrington Hodgkin The PET World Sally Barrington PET-CT Staging in HL PET-CT changes stage 15-30% RATHL - Advanced HL 1171 pts Stage by PET-CT compared with cect and BMB 20% stage change; upstaging 14% Most upstaging

More information

ABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS

ABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy

More information

Update in Lymphoma Imaging

Update in Lymphoma Imaging Update in Lymphoma Imaging Victorine V. Muse, MD Lymphoma Update in Lymphoma Imaging Victorine V Muse, MD Heterogeneous group of lymphoid neoplasms divided into two broad histological categories Hodgkin

More information

Printed by Martina Huckova on 10/3/2011 3:04:43 PM. For personal use only. Not approved for distribution. Copyright 2011 National Comprehensive

Printed by Martina Huckova on 10/3/2011 3:04:43 PM. For personal use only. Not approved for distribution. Copyright 2011 National Comprehensive NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform NCCN consensus. Category 2A: The recommendation

More information

Elderly Patients with Hodgkin s Lymphoma: FIL experience. Massimo Federico University of Modena and Reggio Emilia

Elderly Patients with Hodgkin s Lymphoma: FIL experience. Massimo Federico University of Modena and Reggio Emilia Elderly Patients with Hodgkin s Lymphoma: FIL experience Massimo Federico University of Modena and Reggio Emilia RESULTS OF VbMp CHEMOTHERAPY REGIMEN IN ELDERLY PATIENTS WITH HODGKIN DISEASE: THE GISL

More information

First Line Management of Classical Hodgkin Lymphoma

First Line Management of Classical Hodgkin Lymphoma First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /

More information

Advanced stage HL The old and new match: BEACOPP

Advanced stage HL The old and new match: BEACOPP 27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment

More information

Pediatric Lymphoma Update from the Children s Oncology Group

Pediatric Lymphoma Update from the Children s Oncology Group Pediatric Lymphoma Update from the Children s Oncology Group Stephan D. Voss, MD, PhD Department of Radiology Boston Children s Hospital Harvard Medical School Staging Assessment Disclosures None Acknowledgements:

More information

A Practical Guide to PET adapted Therapy for Hodgkin Lymphoma

A Practical Guide to PET adapted Therapy for Hodgkin Lymphoma Hello. My name is Peter Johnson. I am a Professor of Medical Oncology in Southampton in the UK and I am speaking today on behalf of Managing Hodgkin Lymphoma, and particularly, I am going to talk about

More information

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial H. Eghbali, P.

More information

Hodgkin Lymphoma Review of characteristics and treatment of elderly patients

Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Boris Böll M.D. German Hodgkin Study Group (GHSG) University Hospital Cologne OS of HL patients in all stages 1960-1967 Courtesy

More information

2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA

2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA 2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA SUSQUEHANNA HEALTH David B. Nagel, M.D. April 11, 2008 Hodgkin s lymphoma was first described by Thomas Hodgkin in 1832. It remained an incurable malignancy until

More information

FDG-PET/CT in the management of lymphomas

FDG-PET/CT in the management of lymphomas FDG-PET/CT in the management of lymphomas Olivier Gheysens, MD, PhD Dept. of Nuclear Medicine, UZ Leuven BHS, Feb 4th 2017 Brussels Dept. of Nuclear Overview Introduction on FDG-PET/CT Staging Response

More information

Practical Application of PET adapted Therapy in Hodgkin Lymphoma

Practical Application of PET adapted Therapy in Hodgkin Lymphoma Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,

More information

Role of PET in staging and treatment of lymphomas

Role of PET in staging and treatment of lymphomas Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Lugano, 3-4 November 2017 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging

More information

Hodgkin Lymphoma Status of the art of treatment

Hodgkin Lymphoma Status of the art of treatment 11.05.2016 1 Hodgkin Lymphoma Status of the art of treatment Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Question No 1: Which statement regarding 1 st line treatment of early

More information

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS

More information

Interim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience

Interim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience Interim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience MD. Caballero, Hospital Universitario, Salamanca, Spain. Chair of The GEL/TAMO Group Menton,9 april 2010 Disclosures for Dolores Caballero

More information

REVIEW ARTICLES ABSTRACT. EJD and RBS contributed equally to this manuscript.

REVIEW ARTICLES ABSTRACT. EJD and RBS contributed equally to this manuscript. REVIEW ARTICLES A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin

More information

Early interim PET (PET2) in Hodgkin Lymphoma patients treated with ABVD. An International Validation Study (IVS).

Early interim PET (PET2) in Hodgkin Lymphoma patients treated with ABVD. An International Validation Study (IVS). Early interim PET (PET2) in Hodgkin Lymphoma patients treated with ABVD. An International Validation Study (IVS). A Gallamini Hematology Department and BMT Unit, Santa Croce Hospital Cuneo - Italy S. Barrington

More information

Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma

Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma Original article Annals of Oncology 13: 1908 1914, 2002 DOI: 10.1093/annonc/mdf333 Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma

More information

One, the UK RAPID trial, including patients with early stage disease stage 1 and 2A nonbulky.

One, the UK RAPID trial, including patients with early stage disease stage 1 and 2A nonbulky. Martin Hutchings, MD, PhD Department of Hematology The Finsen Centre, National Hospital Copenhagen University Hospital Copenhagen, Denmark Welcome to Managing Hodgkin Lymphoma. My name is Martin Hutchings.

More information

German Hodgkin Study Group

German Hodgkin Study Group German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of

More information

Dr. Andrea Gallamini - Hematology Department Azienda Ospedaliera S. Croce e Carle Cuneo Italy

Dr. Andrea Gallamini - Hematology Department Azienda Ospedaliera S. Croce e Carle Cuneo Italy High-dose sequential chemotherapy (HDS) followed by autologous stem cell transplantation (ASCT) in relapsed/refractory Hodgkin s lymphoma. Long term results. Dr. Andrea Gallamini - Hematology Department

More information

Overview of Lymphoma Clinical Trials

Overview of Lymphoma Clinical Trials Overview of Lymphoma Clinical Trials Dr Pam McKay Beatson West of Scotland Cancer Centre Lymphoma Action Patient Conference September 2018 Clinical trials medical research involving human participants

More information

THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982)

THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982) EORTC Lymphoma Group THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982) J. Thomas, C. Fermé, E.M. Noordijk, H. Eghbali and M. Henry-Amar 7th International

More information

ROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY

ROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY ROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY EPIDEMIOLOGY HODGKIN LYMPHOMA - INCIDENCE EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY BY AGE NUMBER OF PEOPLE

More information

The Present: Optimizing Therapy Too Much or Too Little?

The Present: Optimizing Therapy Too Much or Too Little? CLINICAL ADVANCES IN HODGKIN LYMPHOMA The Present: Optimizing Therapy Too Much or Too Little? Nancy L. Bartlett 1 1 Siteman Cancer Center, Washington University, St. Louis, MO Despite the use of less toxic

More information

PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be

PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, DC, USA So What is the Question(s)? What is

More information

RT in Hodgkin Lymphoma

RT in Hodgkin Lymphoma RT in Hodgkin Lymphoma Lesser is better? Philip Poortmans, M.D. Ph.D. Radiation oncologist Tilburg, The Netherlands Radiation dose in Hodgkin Lymphoma Introduction Current evidence Guidelines 1.0 Early

More information

What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin

What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering

More information

Hodgkin Lymphoma-Stage III and IV EVIDENCE TABLE

Hodgkin Lymphoma-Stage III and IV EVIDENCE TABLE . Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008. 2. Lister TA, Crowther D, Sutcliffe SB, et al. Report

More information

Workshop key imaging questions

Workshop key imaging questions 11th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Lugano, Switzerland, June 15-18, 2011 Workshop key imaging questions Relevance of current imaging staging systems Influence of tumour burden Need for

More information

NIH Public Access Author Manuscript Expert Opin Pharmacother. Author manuscript; available in PMC 2011 December 1.

NIH Public Access Author Manuscript Expert Opin Pharmacother. Author manuscript; available in PMC 2011 December 1. NIH Public Access Author Manuscript Published in final edited form as: Expert Opin Pharmacother. 2010 December ; 11(17): 2891 2906. doi:10.1517/14656566.2010.515979. Hodgkin s Lymphoma Therapy: Past, Present,

More information

The Importance of PET/CT in Human Health. Homer A. Macapinlac, M.D.

The Importance of PET/CT in Human Health. Homer A. Macapinlac, M.D. The Importance of PET/CT in Human Health Homer A. Macapinlac, M.D. Learning objectives Provide an overview of the impact of PET/CT imaging on the management of patients and its impact on health care expenditures.

More information

Treatment of Early Stage Hodgkin Lymphoma. Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research

Treatment of Early Stage Hodgkin Lymphoma. Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research Treatment of Early Stage Hodgkin Lymphoma Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research Conflict of Interest Disclosure I hereby declare the following

More information

Lugano classification: Role of PET-CT in lymphoma follow-up

Lugano classification: Role of PET-CT in lymphoma follow-up CAR Educational Exhibit: ID 084 Lugano classification: Role of PET-CT in lymphoma follow-up Charles Nhan 4 Kevin Lian MD Charlotte J. Yong-Hing MD FRCPC Pete Tonseth 3 MD FRCPC Department of Diagnostic

More information

First line Treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early versus Advanced Stage Disease Presented

First line Treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early versus Advanced Stage Disease Presented [Editor s note: Dr. Even's video transcript has been edited to improve readability] you today about the management of Hodgkin lymphoma in 2016. Welcome to Managing Hodgkin Lymphoma. My name is Andy Evens,

More information

High incidence of false-positive PET scans in patients with aggressive non-hodgkin s lymphoma treated with rituximab-containing regimens

High incidence of false-positive PET scans in patients with aggressive non-hodgkin s lymphoma treated with rituximab-containing regimens original article 20: 309 318, 2009 doi:10.1093/annonc/mdn629 Published online 7 October 2008 High incidence of false-positive PET scans in patients with aggressive non-hodgkin s lymphoma treated with rituximab-containing

More information

Cure, Late Effects and Prevention in Hodgkin Lymphoma

Cure, Late Effects and Prevention in Hodgkin Lymphoma Cure, Late Effects and Prevention in Hodgkin Lymphoma Michael Crump, MD, FRCPC Princess Margaret Hospital University of Toronto Toronto, Canada Objectives/Outline review progress in treatment of HL outline

More information

End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin s lymphoma

End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin s lymphoma original article Annals of Oncology 22: 910 915, 2011 doi:10.1093/annonc/mdq549 Published online 15 October 2010 original article End-of-treatment but not interim PET scan predicts outcome in nonbulky

More information

Gruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera S. Croce e Carle, Cuneo

Gruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera S. Croce e Carle, Cuneo Sponsor Principal Investigator Protocol Coordinators Coordinating Centre Writing committee CRO Gruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera

More information

Lymphocyte-Depleted Classical Hodgkin s Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group

Lymphocyte-Depleted Classical Hodgkin s Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group Published Ahead of Print on September 12, 211 as 1.12/JCO.211.36.473 The latest version is at http://jco.ascopubs.org/cgi/doi/1.12/jco.211.36.473 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R

More information

Late relapse of Hodgkin s lymphoma is it different in clinical characteristics and outcome?

Late relapse of Hodgkin s lymphoma is it different in clinical characteristics and outcome? JBUON 2017; 22(2): 481-486 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Late relapse of Hodgkin s lymphoma is it different in clinical characteristics

More information

News from EHA. Linfomi. Maurizio Martelli Dip. Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma

News from EHA. Linfomi. Maurizio Martelli Dip. Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma News from EHA Linfomi Maurizio Martelli Dip. Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma Outline HD advanced disease first line therapy : intensity of chemotherapy and PET guided

More information

Bendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service

Bendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)

More information

Poster Discussion : Hodgkin Lymphoma

Poster Discussion : Hodgkin Lymphoma 3 rd INTERNATIONAL WORKSHOP ON INTERIM-PET IN LYMPHOMA Poster Discussion : Hodgkin Lymphoma A. Gallamini T. Vander Borght Hodgkin Lymphoma 1. Technical abstracts Diagnostic criteria (scale, children, when?)

More information

Guidelines for the first line management of classical Hodgkin lymphoma

Guidelines for the first line management of classical Hodgkin lymphoma guideline Guidelines for the first line management of classical Hodgkin lymphoma George A. Follows, 1 Kirit M. Ardeshna, 2 Sally F. Barrington, 3 Dominic J. Culligan, 4 Peter J. Hoskin, 5 David Linch,

More information

FDG PET for therapy response assessment in lymphoma: Beyond Lugano Classification

FDG PET for therapy response assessment in lymphoma: Beyond Lugano Classification FDG PET for therapy response assessment in lymphoma: Beyond Lugano Classification Yan Xuexian, MD, DABNM Department of Nuclear Medicine and PET, SGH National Cancer Center Singapore Duke-NUS Medical School

More information

Clinical Characteristics and Treatment Response of Hodgkin s Lymphoma in Taiwan

Clinical Characteristics and Treatment Response of Hodgkin s Lymphoma in Taiwan ORIGINAL ARTICLE Clinical Characteristics and Treatment Response of Hodgkin s Lymphoma in Taiwan Shang-Ju Wu, 1 Chien-Yuan Chen, 1 Ih-Jen Su, 2 Jih-Luh Tang, 1 Wen-Chen Chou, 1,3 Bo-Sheng Ko, 1 Sheng-Yi

More information

Integrating FDG PET data for lymphoma management. Michel Meignan, France

Integrating FDG PET data for lymphoma management. Michel Meignan, France Integrating FDG PET data for lymphoma management Michel Meignan, France Combining metabolic data from baseline, interim or post treatment PET PET Data can be combined: 1. Together 2. With baseline clinical

More information

Pan-London Haemato-Oncology Clinical Guidelines. Lymphoid Malignancies Part 1: Hodgkin Lymphoma

Pan-London Haemato-Oncology Clinical Guidelines. Lymphoid Malignancies Part 1: Hodgkin Lymphoma Pan-London Haemato-Oncology Clinical Guidelines Lymphoid Malignancies Part 1: Hodgkin Lymphoma September 2018 CONTENTS Contents 1 Introduction... 3 2 Referral Pathways from Primary Care... 3 3 Investigation

More information

Sarajevo (Bosnia Hercegivina) Monday June :30-16:15. PET/CT in Lymphoma

Sarajevo (Bosnia Hercegivina) Monday June :30-16:15. PET/CT in Lymphoma Sarajevo (Bosnia Hercegivina) Monday June 16 2013 15:30-16:15 PET/CT in Lymphoma FDG-avidity Staging (nodal & extra nodal) Response evaluation Early assessment during treatment / interim (ipet) Remission

More information

RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA

RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin

More information

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)

More information

Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL

Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle

More information

Navigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma

Navigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma Welcome to Managing Hodgkin Lymphoma. I am Dr. John Sweetenham from Huntsman Cancer Institute at the University of Utah. In today s presentation, I will be discussing navigating treatment pathways in relapsed

More information

Recommendations for Initial Evaluation, Staging and Response Assessment of Lymphomas

Recommendations for Initial Evaluation, Staging and Response Assessment of Lymphomas Recommendations for Initial Evaluation, Staging and Response Assessment of Lymphomas Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C., USA Disclosures

More information

Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta

Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and

More information

Response Adapted treatment of chl using BV in first line. Massimo Federico University of Modena and Reggio Emilia Italy

Response Adapted treatment of chl using BV in first line. Massimo Federico University of Modena and Reggio Emilia Italy Response Adapted treatment of chl using BV in first line Massimo Federico University of Modena and Reggio Emilia Italy From the book of 18FDG-PET in BV treatment patients 1 In the beginning Seattle Genetics

More information

12 th Annual Hematology & Breast Cancer Update Update in Lymphoma

12 th Annual Hematology & Breast Cancer Update Update in Lymphoma 12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma

More information

Lymphoma update: turning biology into cures. Peter Johnson

Lymphoma update: turning biology into cures. Peter Johnson Lymphoma update: turning biology into cures Peter Johnson Selected highlights of recent research 1. Using FDG-PET to modify treatment and avoid long term toxicity in Hodgkin lymphoma 2. Understanding how

More information

Highlights of ICML 2015

Highlights of ICML 2015 Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465

More information

Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels

Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell

More information

Treatment of Forty Adult Patients with Hodgkin Disease; Baghdad Teaching Hospital Experience

Treatment of Forty Adult Patients with Hodgkin Disease; Baghdad Teaching Hospital Experience Original Article Treatment of Forty Adult Patients with Hodgkin Disease; Baghdad Teaching * Alaadin S. Naji* Ahmed A. AL - Saffar* Mazin A. Shubbar* Bassam F. Matti* Adil Siwan* Ammar F. Majeed* Ali M.Jawad*

More information

Head and Neck: DLBCL

Head and Neck: DLBCL Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD

More information

RADIOLOGY: the chest x-ray

RADIOLOGY: the chest x-ray RADIOLOGY: the chest x-ray A B A case of lymphoma that was treated in September 1901 by W. A. Pusey, Professor of Dermatology in the Medical Department of the University of Illinois. A: The patient on

More information

Update: Non-Hodgkin s Lymphoma

Update: Non-Hodgkin s Lymphoma 2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)

More information

Confronto Real world e studi registrativi

Confronto Real world e studi registrativi Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY

More information

Relapsed/Refractory Hodgkin Lymphoma

Relapsed/Refractory Hodgkin Lymphoma Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage

More information

Deppen S, et al. Annals of Thoracic Surgery 2011;92:

Deppen S, et al. Annals of Thoracic Surgery 2011;92: Deppen S, et al. Annals of Thoracic Surgery 2011;92:428-33. http://www.nationmaster.com/graph/ mor_his-mortality-histoplasmosis http://www.humirarems.com/brochure.aspx Baddley, John W., et al. Emerging

More information

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements

More information

Hodgkin s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease

Hodgkin s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease Hodgkin s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease Volker Diehl, Harald Stein, Michael Hummel, Raphael Zollinger, and Joseph M. Connors Hodgkin s lymphomas

More information

ICML BETALUTIN LYMRIT STUDY UPDATE JUNE 14 TH, 2017

ICML BETALUTIN LYMRIT STUDY UPDATE JUNE 14 TH, 2017 ICML 2017 - BETALUTIN LYMRIT 37-01 STUDY UPDATE JUNE 14 TH, 2017 Disclaimer This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events

More information

Risk, Cure and Complications in Advanced Hodgkin Disease

Risk, Cure and Complications in Advanced Hodgkin Disease Risk, Cure and Complications in Advanced Hodgkin Disease Sandra J. Horning Stanford University, Stanford, CA Current therapy for Hodgkin disease is aimed at high cure rates and optimal survivorship. Although

More information

Linfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP

Linfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of

More information

Radiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2

Radiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2 Radiation and Hodgkin s Disease: A Changing Field Sravana Chennupati Radiation Oncology PGY-2 History of Present Illness 19 yo previously healthy male college student began having pain in his R shoulder

More information

Limited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment

Limited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment HODGKIN LYMPHOMA: CLINICAL CHALLENGES Limited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment John Radford 1 1 Professor of Medical Oncology, Christie Hospital and The University of

More information

Brentuximab Vedotin in Lymphomas

Brentuximab Vedotin in Lymphomas New Drugs In Hematology Brentuximab Vedotin in Lymphomas Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 9:15-9:45 a.m U.S. Cancer Statistics 2016 300.000

More information

Supplementary Appendix to manuscript submitted by Trappe, R.U. et al:

Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful

More information

HODGKIN S LYMPHOMA IN ADULTS AT CHRIS HANI-BARAGWANATH HOSPITAL: A FIFTEEN YEAR REVIEW. Fatima Bibi Fazel

HODGKIN S LYMPHOMA IN ADULTS AT CHRIS HANI-BARAGWANATH HOSPITAL: A FIFTEEN YEAR REVIEW. Fatima Bibi Fazel HODGKIN S LYMPHOMA IN ADULTS AT CHRIS HANI-BARAGWANATH HOSPITAL: A FIFTEEN YEAR REVIEW Fatima Bibi Fazel A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand,

More information

Pros and Cons: Interim PET in DLBCL Ulrich Dührsen Department of Hematology University Hospital Essen

Pros and Cons: Interim PET in DLBCL Ulrich Dührsen Department of Hematology University Hospital Essen 3rd International Workshop on in Lymphoma Menton, September 26, 2011 Afternoon Controversies Pros and Cons: in DLBCL Ulrich Dührsen Department of Hematology University Hospital Essen Pros Is there any

More information

AHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital

AHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure

More information

children and young people:

children and young people: Hodgkin lymphoma in children and young people: State of the art Professor W. Hamish Wallace RHSC 2016 Childhood Cancer 1971-2010 One-, Five- and Ten-Year Actuarial Survival (%), Children (Aged 0-14),

More information

Welcome & Introductions

Welcome & Introductions Living with Hodgkin Lymphoma Welcome & Introductions Dr. Lamar s slides are available for download at www.lls.org/programs, under the program listing. 1 Living with Hodgkin Lymphoma Living with Hodgkin

More information

Brentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center

Brentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Brentuximab Vedotin Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center U.S. Cancer Statistics 2016 300.000 249.260 224.390 200.000 180.890 Incidence 100.000 95.270 76.960

More information

Does BV as part of salvage impact outcome?

Does BV as part of salvage impact outcome? Does BV as part of salvage impact outcome? Craig Moskowitz, MD Steven A. Greenberg Chair in Lymphoma Research Member, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Medical College

More information

Guidelines for management of Pediatric Hodgkin Lymphoma

Guidelines for management of Pediatric Hodgkin Lymphoma Guidelines for management of Pediatric Hodgkin Lymphoma Section of Leukemia/Lymphoma Department of Pediatric Hematology/Oncology King Faisal Specialist Hospital and Research Center Riyadh TABLE OF CONTENTS

More information

Positron Emission Tomography in the Evaluation of Lymphoma

Positron Emission Tomography in the Evaluation of Lymphoma Positron Emission Tomography in the Evaluation of Lymphoma Ora Israel, Zohar Keidar, and Rachel Bar-Shalom Positron emission tomography (PET) using 18 F-fluorodeoxyglucose (FDG) has emerged in recent years

More information

At initial diagnosis, patients with

At initial diagnosis, patients with Malignant Lymphomas Decision Making and Problem Solving Current treatment and immunotherapy of Hodgkin s lymphoma Beate Klimm Roland Schnell Volker Diehl Andreas Engert The treatment of Hodgkin s lymphoma

More information